We report a case of a 24-old patient suffering from HHV6-induced diarrhea after allogeneic SCT. HHV6 is known to cause exanthema subitum in children, 1 a febrile disease associated with a typical rash. Like all herpes viruses HHV6 persists after primary infection for the rest of the life and is usually controlled by the immune system. In an immunocompromised patient HHV6 can reactivate with fever and skin rash 2 too but also cause more severe illness. Cases of interstitial pneumonitis, 3 encephalitis, 4 myelosuppression 5 and a possible association with GVHD 6 have been reported. In addition, reports on HHV6-induced diarrhea 7 have been published. Our patient was allografted with 7.62 Â 10 6 CD34 þ cells per kg from a matched unrelated donor following myeloablative conditioning therapy (BU 16 mg/kg, VP-16 30 mg/kg, CY 120 mg/kg, anti-thymocyte globulin 6 mg/kg) for consolidation therapy of a Burkitt-like lymphoma in second remission. The second remission was obtained by high-dose therapy consisting of carboplatin 1500 mg/m 2 , ifosfamide 14 g/m 2 and VP-16 1500 mg/m 2 and autologous stem cell reinfusion. CYA was given for GVHD prophylaxis. Acyclovir prophylaxis (3 Â 400 mg per day) was initiated on day þ 1. Leukocyte engraftment (41.0 Gpt/l) occurred on day þ 15. On day þ 19 after transplantation he developed fever up to 39.6 1C followed by massive watery diarrhea with stool volumes up to 4000 ml per day. Leukocyte count decreased from 7.45 to 1.92 Gpt/l and a maculopapular exanthem was seen simultaneously. As the diagnosis of acute GVHD was most likely, a gastroscopy and a colonoscopy were performed. Multiple biopsies from stomach, duodenum and colon were obtained. Histopathology showed the picture of an unspecific colitis but no signs of an intestinal GVHD.
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As no bacteriological or classical pathogen was identified (including Clostridium difficile), a viral cause became more likely and empirical therapy with ganciclovir (5 mg/kg, b.i.d.) was initiated on day þ 22 in addition to ongoing imipenem, teicoplanin and metronidazole. The next day a PCR test specific for HHV6 amplified viral sequences from the biopsies taken from colon and esophagus before initiation of the antiviral treatment. After initiation of antiviral therapy diarrhea improved dramatically during the following 24 h and all symptoms (diarrhea, fever and the exanthem) resolved within the following days.
Before PBSCT our patient had tested positive for HHV6-IgG antibodies and negative for HHV6-IgM antibodies, therefore the positive PCR results indicated a viral reactivation (instead of a primary infection). PCR tests of the biopsies for other viruses (HCMV, herpes simplex virus, adenovirus, enterovirus) were negative, also rota-and norovirus could be excluded by antigen testing of stool samples. Blood samples taken the same time as the biopsies showed no amplification of HHV6 or any other virus in the PCR test, so our results could have been classified as a primary intestinal reactivation of HHV6. To confirm those results, the PCR product was sequenced after amplification with nested PCR. 8 Using primers binding in the U31 gene 99% identity with human herpesvirus 6B strain Z29 could be shown.
A review of the literature showed some reports on HHV6 reactivation in patients after PBSCT, and the symptoms reported were similar to those seen in our patient. So far our case is one of the first reports of successful treatment of an ongoing HHV6-induced diarrhea with ganciclovir in a patient after PBSCT. Systematic examination of blood samples showed an HHV6 reactivation in approximately half of the post-BMT patients, about 40% of them were asymptomatic when HHV6 reactivation was detected. 9 Ganciclovir, 10 cidofovir 11 and foscarnet seemed to be effective in treatment of a HHV6 reactivation in post-BMT patients, HHV6 is resistant to acyclovir in doses used under normal clinical conditions. 12 We recommend examining all biopsies taken from post-PBSCT patients suspicious for intestinal GVHD with virus-specific PCR to detect a viral reactivation. 
